Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director comp.
Appointed director
Compass Therapeutics, Inc. (CMPX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 8-K Quarterly results
Docs: "Investor Contact"
05/04/2023 8-K Quarterly results
04/24/2023 8-K Quarterly results
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
02/24/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/10/2023 8-K Quarterly results
01/19/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Investor Contact"
11/29/2022 8-K Quarterly results
11/02/2022 8-K Quarterly results
08/19/2022 8-K Quarterly results
08/01/2022 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits...
Docs: "Open Market Sale AgreementSM , by and between Compass Therapeutics, Inc. and Jefferies LLC",
"Opinion of Goodwin Procter LLP"
05/31/2022 8-K Quarterly results
05/04/2022 8-K Quarterly results
04/26/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "COMPASS THERAPEUTICS ANNOUNCES APPOINTMENT OF TWO NEW DIRECTORS TO ITS BOARD"
02/25/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
01/20/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Compass Therapeutics Announces US FDA Clearance of Investigational New Drug Application for a Phase 2 Study of CTX-009, a Bispecific Antibody That Simultaneously Targets Delta-like Ligand 4 and Vascular Endothelial Growth Factor A"
12/21/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/03/2021 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNDERWRITING AGREEMENT November 1, 2021 SVB Leerink LLC as Representative of the several Underwriters c/o SVB Leerink LLC 53 State Street, 40th Floor Boston, MA 02109",
"100 Northern Avenue Boston, MA 02210",
"Investor Contact"
11/01/2021 8-K Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Compass Reports the Advancement of CTX-009, a Bispecific Antibody, to Phase 2a Development in Patients with Biliary Tract Cancers , and the Clearance of a Key Clinical Hurdle  Phase 2a study was initiated by Handok Pharmaceuticals in Q1 2021 in patients with Biliary Tract Cancers .  Enrollment in the first part of the study has been completed and the criteria to advance to the second part of the study have been met.  Notably, five partial responses have already been observed among the first 17 patients evaluated leading to a preliminary overall response rate of 29% , and all patients evaluated have had stable disease or better with a decline in tumor burden observed in 16 of the 17 patients leading to a Clinical Benefit Rate of 100% .  Compass plans to submi...",
"Investor Contact"
10/08/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "CTX-009 Clinical Data Presented Today at the New Drugs on the Horizon Plenary Session of the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics  CTX-009 was well tolerated and demonstrated single agent activity in heavily pre-treated patients with solid tumor who are resistant to anti-VEGF therapies, mostly of colorectal and gastric origins  The structural differences between CTX-009 and other bispecifics targeting these pathways, as well as the affinities and avidities to their targets, may be the drivers for the differentiated safety and efficacy data observed  The maximum tolerated dose was not reached, and the recommended Phase 2 doses of CTX-009 were determined to be 10.0 and 12.5 mg/kg biweekly  Overall response r..."
06/30/2021 8-K Quarterly results
06/04/2021 8-K Quarterly results
05/13/2021 8-K Quarterly results
04/19/2021 8-K Quarterly results
12/17/2020 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
09/15/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : September 10, 2020 Compass Therapeutics, Inc. Delaware 000-55939 82-4876496 245 First Street, 3rd Floor, Cambridge, Massachusetts 02142 500-8099 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13...",
"Compass Therapeutics, Inc. Provides Corporate Update CAMBRIDGE, Mass., September 15th, 2020 — Compass Therapeutics, Inc. a clinical-stage biotechnology company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies, today announced the promotion of Vered Bisker-Leib, PhD, MBA to President, in addition to her current position as Chief Operating Officer, and the appointment of Brett Kaplan, MD to its Board of Directors and as the Chair of the Audit Committee. “Vered is a strategic and results-oriented leader who has been instrumental in leading Compass through a period of rapid change, which included the achievement of important corporate milestones.” said Thomas Schuetz, MD, PhD, Co-Founder and Chief Execut..."
06/23/2020 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy